⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883346 | 1.00 | — | — | |
| SCHEMBL1884027 | 1.00 | — | — | |
| SCHEMBL28773437 | 0.79 | — | — | |
| SCHEMBL28773434 | 0.79 | — | — | |
| SCHEMBL185739 | 0.75 | — | — | |
| SCHEMBL185738 | 0.75 | — | — | |
| SCHEMBL185737 | 0.75 | — | — | |
| SCHEMBL6941754 | 0.71 | GABBR2 (0.45) | — | |
| SCHEMBL6938427 | 0.71 | GABBR2 (0.45) | — | |
| SCHEMBL5091976 | 0.70 | GABBR2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | claimed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | claimed |
| WO-2006050472-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF 3-AMINOPROPYLPHOSPHONOUS AND -PHOSPHINIC ACIDS | XENOPORT, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| US-6596711-B1 | GABA B receptor agonists for use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and gastroesophogeal reflux | ASTRAZENECA AB (SE) | 2003-07-22 | — | — | US | claimed |
| WO-2002100870-A1 | NEW NAPSYLATE SALTS II | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-7935686-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | XENOPORT, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | disclosed |
| WO-2006071186-A1 | USE OF GABAB RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2004000855-A1 | COMBINATION OF AN ACID SECRETION INHIBITING AGENT AND A REFLUX INHIBITOR FOR THE TREATMENT OF GERD | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000856-A1 | COMBINATION OF A REFLUX INHIBITOR AND AN IMIDAZOPYRIDINE FOR THE TREATMENT OF GERD | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| US-6596711-B1 | GABA B receptor agonists for use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and gastroesophogeal reflux | ASTRAZENECA AB (SE) | 2003-07-22 | — | — | US | disclosed |
| WO-2002100870-A1 | NEW NAPSYLATE SALTS II | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1239843-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001041743-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |